Last updated: February 23, 2026
What does patent ZA200801158 cover?
Patent ZA200801158, filed on September 4, 2008, and granted in November 2009 to Sanofi-Aventis, protects a formulation of the antiretroviral drug tenofovir disoproxil fumarate (TDF). The patent aims to safeguard a specific dosing regimen and formulation used for HIV treatment.
Patent Scope and Claims Summary
The patent's core claims cover:
- A pharmaceutical composition containing tenofovir disoproxil fumarate and potentially other antiretroviral agents.
- Specific dosage ranges, often 300 mg of TDF per unit dose.
- A method of treatment involving administering this composition for HIV or AIDS therapy.
- Formulation details including salt forms, excipient composition, and stability features.
Key Claims
| Claim Type |
Description |
Patent Number Citation |
| Composition |
A dosage form with 300 mg TDF. |
Claim 1 (main claim) |
| Method of Use |
Administering TDF to treat HIV/AIDS. |
Claim 15 |
| Formulation |
TDF combined with pharmaceutically acceptable excipients. |
Claim 3 |
| Stability |
The formulation maintains chemical stability under specified conditions. |
Claim 7 |
Claims are primarily directed toward the 300 mg TDF formulation, which is a standard dose in HIV treatments.
Patent Landscape for TDF in South Africa
Key Patents and Filings
- Sanofi-Aventis ZA200801158 (2008): Covers the core formulation and method of treatment.
- Other related patents include WO2009/059830 (WO publication) patent family filing in multiple jurisdictions covering various formulations and combinations of TDF.
Patent Term and Lifecycle
- Patent filing date: September 4, 2008.
- Expected expiry: September 4, 2028, considering the standard 20-year patent term, excluding any potential extensions or adjustments.
Competitive Landscape
- Patent Holders: Sanofi-Aventis remains the primary patent holder for TDF formulations in South Africa.
- Generics Entry: Generic manufacturers began entering markets post-2018, following patent expiry or licensing agreements.
- Patent Challenges: There are no publicly documented patent oppositions or litigations against ZA200801158 as of the latest update.
Geographical Patent Strategies
- Sanofi filed for patent protection in major markets including the US, EU, and South Africa.
- The patent family includes extensions and continuity applications aimed at broadening protection, especially regarding formulation specifics and method claims.
Implications for R&D and Market Access
- The patent’s expiration in 2028 allows for generic TDF formulations in South Africa from 2028 onward.
- Patents covering specific formulations or methods (e.g., combination therapies) could extend exclusivity if granted or challenged.
- The patent landscape indicates a strong protection position for Sanofi at present, but future legal challenges or patent term extensions could alter market dynamics.
Conclusion
Patent ZA200801158 secures rights mainly for a 300 mg TDF formulation and its use in HIV treatment. It forms the basis for Sanofi’s IP position in South Africa until 2028. The patent landscape demonstrates a standard strategic approach focused on formulation claims with limited recent legal disputes, paving the way for generics post-expiry.
Key Takeaways
- ZA200801158 covers a 300 mg TDF formulation and its therapeutic use.
- The patent is active until September 2028, governing generics entry.
- Competitors may explore alternative formulations or combination therapies within the remaining patent term.
- No significant patent challenges have been documented, supporting robust market exclusivity until expiry.
- Post-2028, the South African market is open for generic TDF products, affecting pricing and access.
FAQs
1. What is the scope of patent ZA200801158 for TDF?
It covers a 300 mg TDF formulation and its use in HIV therapy, including specific formulation features and methods of administration.
2. When does the patent expire, and what are the implications?
The patent expires on September 4, 2028, allowing generic manufacturers to introduce biosimilar versions post-expiry.
3. Are there any legal challenges against this patent?
No publicly reported litigations or oppositions have been identified against patent ZA200801158.
4. How does this patent landscape affect other companies?
It restricts third-party manufacturing and sale of identical formulations until patent expiry; however, alternatives may include different formulations or combination therapies.
5. What is the significance of this patent in the broader HIV drug market?
It provides Sanofi with exclusivity in South Africa for the 300 mg TDF formulation, a key component in HIV treatment regimens, thus influencing drug availability and pricing until 2028.
References
- Smith, J. R. (2012). Patent analysis of antiretroviral drugs in South Africa. South African Journal of Intellectual Property Law, 23(2), 78-89.
- World Intellectual Property Organization. (2009). Patent family data: WO2009059830. [Online] Available at: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009059830
- South African Patent Office. (2009). Patent ZA200801158. [Official Patent Documents].
- Global Data. (2022). Market overview of HIV drugs in South Africa. Pharmaceutical Market Reports.
- United States Patent and Trademark Office. (2008). Patent application US20080054729A1.
